DURHAM, NC, Levee MedicalĀ®, a medical device company focused on improving outcomes for prostate cancer surgery patients, announced the successful close of its Series B financing.
Levee MedicalĀ® announced the successful close of its Series B financing, totaling more than $14 million including note conversions. This fundraising round highlights strong investor confidence in the company's innovative solution for post-prostatectomy incontinence.
Levee Medical is committed to designing solutions that aim to reduce complications associated with surgical treatment for prostate cancer. The Voro Urologic Scaffold is the first product Levee plans to bring to market. This device is an investigational device, is not FDA cleared or approved and is currently in the research and development phase and is not available for sale in any country.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
